Literature DB >> 12239835

A pilot study on the seroprevalence of parvovirus B19 infection.

Mary Abraham1, Rajeev Rudraraju, Rajesh Kannangai, Koshy George, Thomas Cherian, Dolly Daniel, Sandeep Ramalingam, Gopalan Sridharan.   

Abstract

BACKGROUND &
OBJECTIVES: Human parvovirus B 19 (PVB 19) causes aplastic crisis in children with congenital haemolytic anaemia, erythema infectiosum, abortion and stillbirth. Since data on PVB 19 prevalence is lacking in India, a pilot study was undertaken to estimate the prevalence of IgG antibody in children and adults.
METHODS: The samples were obtained from children attending our hospital and from volunteer blood donors, majority of whom were from south India. They included 45 children aged 1-5 yr, 39 aged 6-10 yr, 42 aged 11-15 yr and 100 healthy blood donors > 15 yr of age. Sera were tested for the presence of antibody to PVB 19 using a commercial enzyme immuno assay (EIA).
RESULTS: Of 226 samples tested, 113 (50%) were positive for PVB 19 IgG. The prevalence of antibody increased from 8.9 per cent at 1-5 yr to 70 per cent in those > 15 yr: the median age of infection was between 6 and 15 yr. Sex and domiciliary status did not have significant effect on the prevalence of antibody. The IgG antibody index increased significantly with age, suggesting repeated exposure to the virus. INTERPRETATION &
CONCLUSION: This seroprevalence study indicates that large numbers of individuals show exposure to PVB 19 virus. The exposure as indicated by IgG positivity is seen to increase with age. The IgG negative individuals may be considered to be at risk of developing infections due to PVB 19.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12239835

Source DB:  PubMed          Journal:  Indian J Med Res        ISSN: 0971-5916            Impact factor:   2.375


  9 in total

1.  Prevalence of Parvovirus B19V in Hematological Malignancies and Chronic Anemia.

Authors:  Amita Jain; Parul Jain; Shantanu Prakash; Danish N Khan; Archana Kumar; Ravi Kant
Journal:  Indian J Pediatr       Date:  2017-08-02       Impact factor: 1.967

2.  Seroepidemiology of parvovirus B19 among different age groups & pregnant women in India.

Authors:  Rajlakshmi Viswanathan; Babasaheb V Tandale; Manisha S Tamayachekar; Santoshkumar M Jadhav; Kirtee A Khutwad; Kiran R Munne
Journal:  Indian J Med Res       Date:  2017-07       Impact factor: 2.375

3.  SEROPREVALENCE OF ERYTHROVIRUS B19 IgG AMONG SAUDI BLOOD DONORS IN MAKKAH, SAUDI ARABIA.

Authors:  Ayman K Johargy
Journal:  J Family Community Med       Date:  2009-09

4.  Standardization of B19 IgG ELISA to study the seroepidemiology of parvovirus B19 in North Indian voluntary blood donors.

Authors:  Janak Kishore; Manisha Srivastava; Nabjyoti Choudhary
Journal:  Asian J Transfus Sci       Date:  2010-07

5.  A pilot study on parvovirus B19 infection in paediatric haematological malignancies.

Authors:  Janak Kishore; Manodeep Sen; Ashutosh Kumar; Archana Kumar
Journal:  Indian J Med Res       Date:  2011-04       Impact factor: 2.375

6.  Identification and Genomic Characterization of Parvovirus B19V Genotype 3 Viruses from Cases of Meningoencephalitis in West Bengal, India.

Authors:  Chitra Pattabiraman; Pramada Prasad; Sampada Sudarshan; Anson K George; Darshan Sreenivas; Risha Rasheed; Ayushman Ghosh; Ananya Pal; Shafeeq K Shahul Hameed; Bhaswati Bandyopadhyay; Anita Desai; Ravi Vasanthapuram
Journal:  Microbiol Spectr       Date:  2022-04-12

7.  Development & standardization of an in-house IgM indirect ELISA for the detection of parvovirus B19 infections.

Authors:  Kumaran Vadivel; Mageshbabu Ramamurthy; Sathish Sankar; Amita Jain; Padma Srikanth; Asit Ranjan Ghosh; Balaji Nandagopal; Aravindan Nair; Gopalan Sridharan
Journal:  Indian J Med Res       Date:  2017-09       Impact factor: 2.375

8.  Seroprevalence of erythrovirus B19 in Saudi pregnant women.

Authors:  Ayman K Johargy
Journal:  J Family Community Med       Date:  2016 May-Aug

9.  Persistence of human parvovirus B19 in tissues from adult individuals: a comparison with serostatus and its clinical utility.

Authors:  R Aravindh; Uma Nahar Saikia; Baijayantimala Mishra; Vandana Kumari; Subhabrata Sarkar; Mirnalini Sharma; Radha Kanta Ratho; Kusum Joshi
Journal:  Arch Virol       Date:  2014-04-30       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.